Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03082768 · ClinicalTrials.gov registry record · Early Phase 1
Phase 0 Study of [18F]MNI-968 as a Marker for D1 Receptor in Healthy Subjects
A Early Phase 1 study of Healthy Volunteers, sponsored by Molecular NeuroImaging.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT03082768 is a Early Phase 1 study of Healthy Volunteers that has completed, run by Molecular NeuroImaging. The registered enrollment target is 6 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03082768, a Early Phase 1 study of Healthy Volunteers, has completed, sponsored by Molecular NeuroImaging.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall goal of this protocol is to evaluate \[18F\]MNI-968 (aka PF-06730110) as a D1 receptor targeted radiopharmaceutical.
Conditions Studied
Interventions
- DRUG [18F]MNI-968
Study Locations (1)
Connecticut
- Molecular NeuroImaging, LLC - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-03-03 |
| Est. Completion | 2018-03-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03082768
The ClinicalTrials.gov registry entry for NCT03082768 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (99% lower). The listed sponsor is Molecular NeuroImaging, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 1 intervention - of which [18F]MNI-968 is the first listed.
NCT03082768 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT03082768 about?
NCT03082768 is a clinical study titled "Phase 0 Study of [18F]MNI-968 as a Marker for D1 Receptor in Healthy Subjects". The overall goal of this protocol is to evaluate \[18F\]MNI-968 (aka PF-06730110) as a D1 receptor targeted radiopharmaceutical.
What is the current status of trial NCT03082768?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2017-03-03. Estimated completion is 2018-03-01.
What conditions does trial NCT03082768 study?
This clinical trial studies the following conditions: Healthy Volunteers.
What interventions are being tested in trial NCT03082768?
The interventions under investigation include: [18F]MNI-968 (DRUG).
Who is sponsoring clinical trial NCT03082768?
This trial is sponsored by Molecular NeuroImaging, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03082768 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Human Milk Oligosaccharide-Based Synbiotic Supplement for Intestinal Microbiota Dysbiosis
RECRUITING · Early Phase 1
-
Chronic Transcutaneous Stimulation to Promote Motor Function and Recovery in Individuals With Paralysis or Paresis
RECRUITING · Early Phase 1
-
Sustained Release Oral Formulation for Treatment of Parkinson's Disease
RECRUITING · Early Phase 1
-
Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein
COMPLETED · Early Phase 1
-
Testing Potential Synergistic Effects of Albuterol and Caffeine on Metabolic Rate
COMPLETED · Early Phase 1
-
Adaptive Optics Retinal Imaging
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.